《ALK阳性NSCLC全程化管理-OS获益最大化》.pptVIP

ALK阳性NSCLC全程化管理 —如何让患者OS获益最大化 ;PROFILE 1014: 克唑替尼（Crizotinib)与以铂为基础的化疗在未经治疗的ALK 阳性非小细胞肺癌患者中的III期研究: OS数据的更新;PROFILE 1014研究背景;PROFILE 1014 研究设计;aThere were no significant differences between the groups in any of the characteristics listed in this table; bRace was self-reported; CECOG PS was assessed at the time of screening; the score was not reported for one patient in the crizotinib group. Scores range from 0 to 5, with higher scores indicating increasing disability; an ECOG PS of 0 indicates that the patient is fully active, 1 that the patient is ambulatory but restricted in strenuous activity, and 2 that the patient is ambulatory and capable of self-care but is unable to work.; ;;;如果未进行交叉治疗 患者的OS结果如何?;;;;总生存率(%);;通过对两组患者近46个月的中位随访，该研究获得了迄今为止所有IV期NSCLC患者最高的4年生存率数据； 克唑替尼组与化疗组的OS差异无统计学意义 (HR：0.760 [95% CI: 0.548, 1.053])； 克唑替尼治疗后序贯其他TKI药物治疗组的OS最长，而化疗后序贯非TKI或者其他治疗OS最差； 化疗不是理想的一线治疗方案； 长期克唑替尼治疗未发现意外不良反应。;Crizotinib / Ceritinib / Alectinib 哪个是ALK阳性NSCLC一线首选TKI？;优选PFS？;CRIZOTINIB;晚期NSCLC靶向治疗和标准治疗研究显示：ORR与OS、PFS与OS之间无关联;Alex 试验;剖析一代和二代ALK-TKI不同耐药机制;Crizotinib-resistant cases;;ALK阳性的NSCLC患者中crizotinib和alectinib的序贯治疗：多中心回顾性研究;;总 结 ;dsfdbsy384y982ythb3oibt4oy39y409705923y09y53b2lkboi2y58wy0ehtoibwoify98wy049ywh4b3oiut89u983yf9ivh98y98sv98hv98ys9f698y9v698yv98x98tb98fyd98gyd98h98ds98nt98d8genklgb4klebtlkb5k tkeirh893y89ey698vhkrne lkhgi8eyokbnkdhf98hodf hxvy78fd678t9fdu90gys98y9shihixyv78dfhvifndovhf9f8yv9onvkobkw kjfegiudsfdbsy384y982ythb3oibt4oy39y409705923y09y53b2lkboi2y58wy0ehtoibwoify98wy049ywh4b3oiut89u983yf9ivh98y98sv98hv98ys9f698y9v698yv98x98tb98fyd98gyd98h98ds98nt98d8genklgb4klebtlkb5k tkeirh893y89ey698vhkrne lkhgi8eyokbnkdhf98hodf hxvy78fd678t9fdu90gys98y9shihixyv78dfhvifndovhf9f8yv9onvkobkw kjfegiu dsfdbsy384y982ythb3oibt4oy39y409705923y09y53b2lkboi2y58wy0ehtoibwoify98wy049ywh4b3oiut89u983yf9ivh98y98sv98hv98ys9f698y9v698yv98x98tb98fyd98gyd98h98ds98nt98d8gen;56384866666gjfdghmghm56384866666gjfdghmghm56384866666gjfdghmghm56